MLAB Stock Analysis: Mesa Laboratories | NASDAQ

Sterilization Indicators, Protein Analysis, Genetic Analysis, Calibration Instruments

Total Rating 57

Safety 66

Buy Signal 0.16

Scientific & Technical Instruments
Industry Rotation: +0.4

Market Cap: 720M
Avg Turnover: 11.6M

Risk 3d forecast

Volatility53.3%

VaR 5^th Pctl8.76%

VaR vs Median-0.18%

Reward TTM

Sharpe Ratio1.19

Rel. Str. IBD93.6

Rel. Str. Peer Group61.7 pctl

Character TTM

Beta1.149

Beta Downside1.022

Hurst Exponent0.379

Choppyness49.8%

Drawdowns 3y

Max DD62.78%

CAGR/Max DD0.23

CAGR/Mean DD0.58

EPS (Earnings per Share)

EPS CAGR: 5.36%
EPS Trend: 21.2%

Last SUE: -0.70
Qual. Beats: 0

Revenue

Rev. CAGR: 6.84%
Rev. Trend: 96.6%

Last SUE: -0.39
Qual. Beats: 0

Warnings

P/E Ratio 151.4

Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Seasonality 11.7 years of data

Jan +2.7% 18

Feb -5.4% 6

Mar -0.5% 8

Apr +1.1% 2

May -3.1% 21

Jun -1.9% 21

Jul +2.1% 32

Aug -3.5% 25

Sep +2.6% 21

Oct -0.8% 16

Nov +0.4% 13

Dec +2.1% 31

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: MLAB Mesa Laboratories

Mesa Laboratories, Inc. (NASDAQ: MLAB) is a U.S.-based small-cap health care company in the Life Sciences Tools & Services sub-industry, headquartered in Lakewood, Colorado and incorporated in 1982. The company operates through four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Clinical Genomics, and Calibration Solutions, serving pharmaceutical, medical device, healthcare, and industrial customers across North America, Europe, and Asia Pacific.

The Sterilization and Disinfection Control segment supplies biological, chemical, and cleaning indicators used to validate sterilization and decontamination processes, along with sterility assurance testing and laboratory services for dental and pharmaceutical clients. Sterilization monitoring is a regulated quality control requirement in pharmaceutical and medical device manufacturing, making recurring indicator consumption a key revenue driver for the segment.

The Biopharmaceutical Development segment offers automated immunoassay systems (Gyrolab xPand, Gyrolab xPlore) with associated microfluidic consumables, kits, and buffers for protein analysis, plus PurePep Symphony and Chorus instruments for peptide synthesis. The Clinical Genomics segment provides the MassARRAY genetic analysis platform and related chips, panels, and reagent kits used by clinical laboratories for hereditary disease screening, pharmacogenetics, oncology, and toxicology applications.

The Calibration Solutions segment markets quality control instruments and continuous monitoring systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands, used for renal care, gas flow, environmental and process monitoring, and torque testing. Across its portfolio, Mesas business model is anchored in regulatory-driven, recurring consumables and service revenue tied to ongoing quality and compliance requirements in customer production processes.

Headlines to Watch Out For

Gyrolab biopharma segment growth offsets legacy revenue declines
FDA compliance costs pressure margins at Bozeman manufacturing facility
Sterilization indicator demand tracks pharma and medical device production

Piotroski VR-10 (Strict) 6.0

Net Income: 4.80m TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 5.66 > 1.0
NWC/Revenue: 21.30% < 20% (prev -21.14%; Δ 42.45% < -1%)
CFO/TA 0.13 > 3% & CFO 55.7m > Net Income 4.80m
Net Debt (117.4m) to EBITDA (40.6m): 2.89 < 3
Current Ratio: 2.07 > 1.5 & < 3
Outstanding Shares: last quarter (5.76m) vs 12m ago 3.67% < -2%
Gross Margin: 65.99% > 18% (prev 60.29%; Δ 5.70% > 0.5%)
Asset Turnover: 58.42% > 50% (prev 55.62%; Δ 2.80% > 0%)
Interest Coverage Ratio: 1.62 > 6 (EBIT TTM 17.6m / Interest Expense TTM 10.9m)

Altman Z'' 0.54

A: 0.13 (Total Current Assets 102.8m - Total Current Liabilities 49.6m) / Total Assets 419.2m
B: -0.44 (Retained Earnings -183.8m / Total Assets 419.2m)
C: 0.04 (EBIT TTM 17.6m / Avg Total Assets 427.5m)
D: 0.82 (Book Value of Equity 188.8m / Total Liabilities 230.5m)
Altman-Z'' = 0.54 = B

Beneish M -3.23

DSRI: 0.85 (Receivables 34.4m/39.1m, Revenue 249.7m/242.4m)
GMI: 0.91 (GM 60.29% / 65.99%)
AQI: 0.97 (AQ_t 0.68 / AQ_t-1 0.70)
SGI: 1.03 (Revenue 249.7m / 242.4m)
TATA: -0.12 (NI 4.80m - CFO 55.7m) / TA 419.2m)
Beneish M = -3.23 (Cap -4..+1) = AA

What is the price of MLAB shares?

As of October 29, 2026, the stock is trading at USD 131.32 with a total of 143,437 shares traded. Over the past week, the price has changed by +1.64%, over one month by -1.26%, over three months by +30.05% and over the past year by +69.65%.

Current recommended Stop Loss: 118.70 (which is 9.6% or 2.7 ATR below the current price).

Is MLAB a buy, sell or hold?

Mesa Laboratories has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy MLAB.

StrongBuy: 1
Buy: 0
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the MLAB price?

Analysts Target Price	125	-4.8%

Mesa Laboratories (MLAB) - Fundamental Data Overview as of 27 October 2026

Market Cap USD = 720.0m (720.0m USD * 1.0 USD.USD)
P/E Trailing = 151.3647
P/E Forward = 35.2113
P/S = 2.883
P/B = 3.9915
Revenue TTM = 249.7m USD
EBIT TTM = 17.6m USD
EBITDA TTM = 40.6m USD
Long Term Debt = 137.2m USD (from longTermDebt, last quarter)
Short Term Debt = 8.26m USD (from shortTermDebt, last quarter)
Debt = 148.1m USD (corrected: LT Debt 137.2m + ST Debt 8.26m) + Leases 2.63m
Net Debt = 117.4m USD (calculated: Debt 148.1m - CCE 30.7m)
Enterprise Value = 837.4m USD (720.0m + Debt 148.1m - CCE 30.7m)
Interest Coverage Ratio = 1.62 (Ebit TTM 17.6m / Interest Expense TTM 10.9m)
EV/FCF = 14.92x (Enterprise Value 837.4m / FCF TTM 56.1m)
FCF Yield = 6.70% (FCF TTM 56.1m / Enterprise Value 837.4m)
FCF Margin = 22.47% (FCF TTM 56.1m / Revenue TTM 249.7m)
Net Margin = 1.92% (Net Income TTM 4.80m / Revenue TTM 249.7m)
Gross Margin = 65.99% ((Revenue TTM 249.7m - Cost of Revenue TTM 84.9m) / Revenue TTM)
Gross Margin QoQ = 64.87% (prev 73.21%)
Tobins Q-Ratio = 2.00 (Enterprise Value 837.4m / Total Assets 419.2m)
Interest Expense / Debt = 7.33% (Interest Expense 10.9m / Debt 148.1m)
Taxrate = 48.69% (4.55m / 9.36m)
NOPAT = 9.04m (EBIT 17.6m * (1 - 48.69%))
Current Ratio = 2.07 (Total Current Assets 102.8m / Total Current Liabilities 49.6m)
Debt / Equity = 0.78 (Debt 148.1m / totalStockholderEquity, last quarter 188.8m)
Debt / EBITDA = 2.89 (Net Debt 117.4m / EBITDA 40.6m)
Debt / FCF = 2.09 (Net Debt 117.4m / FCF TTM 56.1m)
Total Stockholder Equity = 185.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.12% (Net Income 4.80m / Total Assets 419.2m)
RoE = 2.59% (Net Income TTM 4.80m / Total Stockholder Equity 185.0m)
RoCE = 5.47% (EBIT 17.6m / Capital Employed (Equity 185.0m + L.T.Debt 137.2m))
RoIC = 2.47% (NOPAT 9.04m / Invested Capital 365.3m)
WACC = 8.52% (E(720.0m)/V(868.1m) * Re(9.50%) + D(148.1m)/V(868.1m) * Rd(7.33%) * (1-Tc(0.49)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.02 | Cagr: 2.94%
[DCF] Terminal Value 77.42% ; FCFF base≈47.1m ; Y1≈54.0m ; Y5≈79.5m
[DCF] Fair Price = 186.6 (EV 1.16b - Net Debt 117.4m = Equity 1.04b / Shares 5.60m; r=8.52% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 21.20 | EPS CAGR: 5.36% | SUE: -0.70 | # QB: 0
Revenue Correlation: 96.59 | Revenue CAGR: 6.84% | SUE: -0.39 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.24 | Chg30d=-17.95% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-12-31): EPS=2.71 | Chg30d=-18.62% | Revisions=-25% | Analysts=1
EPS current Year (2027-03-31): EPS=9.95 | Chg30d=-14.37% | Revisions=-25% | GrowthEPS=+19.2% | GrowthRev=+2.1%
EPS next Year (2028-03-31): EPS=10.27 | Chg30d=-16.30% | Revisions=-25% | GrowthEPS=+3.2% | GrowthRev=+6.5%